CELLVICROHN study: Is there a concordance between the Cellvizio with an intravenous injection of fluorescein and the pathology to determine the microscopic inflammation at the ileal resection margins in Crohn’s ileal disease.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517220-19-00

Acronym

PI2022_843_0111

Enrollment

Registered

2024-08-22

Start date

2023-10-31

Completion date

Unknown

Last updated

2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's ileal disease

Brief summary

is the microscopically healthy or inflammatory character of the ileal mucosal section margin for Cellvizio and pathology.

Detailed description

The concordance between the Cellvizio with an intravenous injection of fluorescein and the pathology for the inflammation of the serosa (transmural inflammation) and of the mesentery and the length of ileum (in cm) between the surgical margin and the theorical resection site to be in a non-inflammatory area at the Cellvizio (on the mucosa and on the serosa)..

Interventions

DRUGFLUOCYNE 10%

DRUGsolution injectable I.V.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
is the microscopically healthy or inflammatory character of the ileal mucosal section margin for Cellvizio and pathology.	—

Secondary

Measure	Time frame
The concordance between the Cellvizio with an intravenous injection of fluorescein and the pathology for the inflammation of the serosa (transmural inflammation) and of the mesentery and the length of ileum (in cm) between the surgical margin and the theorical resection site to be in a non-inflammatory area at the Cellvizio (on the mucosa and on the serosa)..	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026